Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
OBJECTIVE
The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT).


METHODS
Twelve patients were enrolled in a phase I study using 50.4 Gy RT concurrent with capecitabine chemotherapy (twice daily, 7 days per week) and oxaliplatin (once weekly during weeks 1, 2, 4, and 5). Capecitabine and oxaliplatin doses were 400 mg/m(2) and 50 mg/m(2), respectively, at dose level 1; 600 mg/m(2) and 50 mg/m(2) at level 2; and 600 mg/m(2) and 60 mg/m(2) at level 3. A standard dose of gemcitabine was recommended following RT or following surgery (if done). The outcomes of patients treated with this regimen were retrospectively compared to 20 patients treated with 5FU-RT and 30 patients treated with GEM-RT.


RESULTS
Dose level 3 was tolerated with acceptable toxicity. Survival in patients receiving CAPOX-RT did not differ from GEM-RT or 5FU-RT. Response of the primary tumor was observed in 38% of patients treated with CAPOX-RT, 31% of patients treated with 5FU-RT, and 66% of patients treated with GEM-RT (p = 0.03 GEM-RT versus 5FU-RT).


CONCLUSIONS
CAPOX-RT has acceptable toxicity. A retrospective comparison shows higher response rate with GEM-RT versus 5FU-RT, but this difference did not translate into improvement in overall survival.
Department of Radiation Oncology, University of Arizona, Tucson, AZ 85724-5081, USA. lhazard@email.arizona.edu
Lisa
L
Hazard
Kimberly
K
Jones
Akram
A
Shaban
Christopher
C
Anker
Courtney
C
Scaife
John
J
Weis
Sean
S
Mulvihill
D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D059248:Chemoradiotherapy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000628:therapy*; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D016896:Treatment Outcome; D000093542:Gemcitabine
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil; D000093542:Gemcitabine
J Clin Oncol. 1985 Mar;3(3):373-8
3973648
J Clin Oncol. 2008 Feb 20;26(6):942-7
18281668
Cancer. 1981 Oct 15;48(8):1705-10
7284971
Anticancer Res. 2000 Sep-Oct;20(5A):3259-64
11062751
Ann Oncol. 2008 Feb;19(2):340-7
17962204
Radiother Oncol. 2010 Jun;95(3):292-7
20451275
Anticancer Drugs. 1997 Oct;8(9):876-85
9402315
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):974-80
12829132
Mol Cancer Ther. 2002 Oct;1(12):1139-45
12481438
Eur J Cancer. 1998 Jul;34(8):1274-81
9849491
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104
12909221
Clin Cancer Res. 2001 Aug;7(8):2246-53
11489798
J Natl Cancer Inst. 1988 Jul 20;80(10):751-5
2898536
Int J Gastrointest Cancer. 2001;30(3):123-32
12540024
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
J Clin Oncol. 2001 Nov 15;19(22):4202-8
11709563
Ann Oncol. 2004 Mar;15(3):467-73
14998850
Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1293-302
11955742
Br J Cancer. 2004 Aug 16;91(4):673-7
15226765
Ann Oncol. 2008 Sep;19(9):1592-9
18467316
J Clin Oncol. 1997 Jun;15(6):2403-13
9196156
Cancer Chemother Pharmacol. 2001 May;47(5):415-22
11391857
Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):10-5
12826246